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Abstract
Mitochondrial dysfunction is an early pathological feature of Alzheimer’s disease (AD). The
underlying mechanisms and strategies to repair it remain unclear. Here, we demonstrate for the
first time the direct consequences and potential mechanisms of mitochondrial functional defects
associated with abnormal mitochondrial dynamics in AD. Using cytoplasmic hybrid (cybrid)
neurons with incorporated platelet mitochondria from AD and age-matched non-AD human
subjects into mitochondrial DNA (mtDNA)-depleted neuronal cells, we observed that AD cybrid
cells had significant changes in morphology and function; such changes associate with altered
expression and distribution of dynamin-like protein (DLP1) and mitofusin 2 (Mfn2). Treatment
with antioxidant protects against AD mitochondria-induced extracellular signal-regulated kinase
(ERK) activation and mitochondrial fission-fusion imbalances. Notably, inhibition of ERK
activation not only attenuates aberrant mitochondrial morphology and function but also restores
the mitochondrial fission and fusion balance. These effects suggest a role of oxidative stress-
mediated ERK signal transduction in modulation of mitochondrial fission and fusion events.
Further, blockade of the mitochondrial fission protein DLP1 by a genetic manipulation with a
dominant negative DLP1 (DLP1K38A), its expression with siRNA-DLP1, or inhibition of
mitochondrial division with mdivi-1 attenuates mitochondrial functional defects observed in AD
cybrid cells. Our results provide new insights into mitochondrial dysfunction resulting from
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changes in the ERK-fission/fusion (DLP1) machinery and signaling pathway. The protective
effect of mdivi-1 and inhibition of ERK signaling on maintenance of normal mitochondrial
structure and function holds promise as a potential novel therapeutic strategy for AD.
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1. Introduction
Alzheimer’s disease (AD) is the most common form of dementia characterized clinically
progressive cognitive decline and neuronal loss. Pathologically, AD-affected brain shows
accumulation of amyloid beta peptide (Aβ) and neurofibrillary tangles with tau
hyperphosphorylation. Recent studies indicate that mitochondrial dysfunction, an early
pathological feature in AD, plays a central role in its pathogenesis of AD [1–6]. Perturbed
bioenergetic function, especially mitochondrial dysfunction, is seen in brain and peripheral
tissues of subjects with AD [7, 8]. Cytochrome c oxidase (CcO) activity is lower in human
AD platelet mitochondria [8–10]. Neurons are especially vulnerable to mitochondrial
dysfunction due to inherent high energy demands and dependence on respiration for ATP
generation [3, 11]. Thus, mitochondrial dysfunction may drive or mediate various AD
pathologies.
Mitochondria are dynamic organelles that undergo continuous fission and fusion. These
processes are regulated by the large dynamin-related GTPases mitofusin 1 and 2 (Mfn1 and
2), and optic atrophy1 (OPA1) for fusion and dynamin-like protein (DLP1) for fission [12,
13]. Mitochondrial dynamics play an essential role in ensuring appropriate distribution of
mitochondria within cells, a function that is particularly critical for morphologically
complex cells such as neurons [14]. Alterations in mitochondrial dynamics significantly
impact almost all aspects of mitochondrial function including energy metabolism, calcium
buffering, reactive oxygen species (ROS) generation and apoptosis regulation [12, 15].
Imbalance of mitochondrial fission and fusion is an important mechanism in
neurodegenerative diseases including Parkinson disease (PD), Huntington disease (HD), and
AD. Although it has been demonstrated that altered mitochondrial fission or fusion is
involved in Aβ-mediated mitochondrial morphological changes leading to neuronal and
synaptic dysfunction in a transgenic AD mouse model and in vitro cell culture [15–17], the
direct consequences and mechanisms underlying AD-derived mitochondrial defects on
mitochondrial dynamics and associated mitochondrial function have not been fully
elucidated. The following questions arise: Do AD-derived mitochondria show changes in
mitochondrial fission and fusion events? If so, are these altered mitochondrial dynamics
associated with mitochondrial dysfunction? Does inhibition of abnormal mitochondrial
fusion and fission rescue aberrant mitochondrial morphology and function? Thus, it is
essential to uncover the mechanism by which AD mitochondria modulate this vital
mitochondrial process.
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To explore the mechanisms associated with AD-specific mitochondrial defects, we used
cybrid cells with incorporated platelet mitochondria from AD or age-matched non-AD
human subjects into mitochondrial DNA (mtDNA)-depleted neuronal cells (SH-SY5Y). The
resulting cell lines, referred to as AD or non-AD cybrids, have been demonstrated to have
different bioenergetic profiles [7]. AD cybrids recapitulate many potential pathogenic
features of AD, such as decreased activity associated with respiratory chain key enzyme,
increased free radical production rates, and other functional changes that likely arise as a
consequence of perturbed respiratory chain function typically observed in AD brain
mitochondria [18, 19].
Using AD cybrids, we comprehensively evaluated the consequences of changes in AD-
specific mitochondria on mitochondrial dynamics and mitochondrial function. We further
delineated the mechanism by which AD mitochondria regulate mitochondrial fission/fusion
events. Our investigation provides new insight into the role of mitochondrial dynamics in
AD pathogenesis, highlighting the potential diagnostic and therapeutic application for AD.
2. Material and methods
2.1 Human subjects and creation of cybrid cell lines
Individuals for this study were recruited from the University of Kansas Alzheimer’s Disease
Center. AD subjects met the National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria
[20]. Non-AD subjects were cognitively normal and age-matched to AD subjects. This study
was approved by the University of Kansas Medical Center (KUMC) Institutional Review
Board. All subjects provided written informed consent to participate in the study. The ages
of AD and non-AD subject platelet donors were 73.3 ± 2.6 and 74 ± 2.9 years, respectively.
Gender, age and disease status of donor patients are presented in supplemental Table. S1.
Cybrid cell lines were created on the human neuroblastoma cell (SH-SY5Y) nuclear
background (by the KU ADC Mitochondrial Genomics and Metabolism Core) [21]. To
create the cybrid cell lines used for this study, SH-SY5Ycells that were previously depleted
of endogenous mtDNA (Rho0 cells) were fused with the platelet cytoplasm and repopulated
with mitochondria containing mtDNA from patients or controls as previously described
[22]. Briefly, Rho0 cells were incubated with donor platelets in a DMEM-polyethylene
glycol solution. Immediately after this, cells were initially placed in Dulbecco's Modified
Eagle Medium (DMEM) supplemented with 10% non-dialyzed fetal bovine serum (FBS),
200µg/ml sodium pyruvate, 150 µg/ml uridine, and 1% penicillin–streptomycin solution to
recover. Seven days after the fusion event, cells were switched to a selection medium
containing 10% dialyzed fetal calf serum but lacking pyruvate and uridine. These conditions
resulted in selection against Rho0 cells that were not repopulated with donor mitochondria.
Only cells containing patient’s platelet mtDNA can regain aerobic competence and survive
the subsequent selection processes. Following selection, each cybrid cell line was
maintained in medium containing DMEM supplemented with 10% non-dialyzed FBS and
1% penicillin-streptomycin solution in a humidified 95% air/5% CO2 incubator at 37°C for
over 2 months. The quantitative real-time PCR showed that the intact mtDNA copies were
Gan et al. Page 3






















present in all cybrids without detectable large scale deletion after many passages of cell
proliferation (Fig. S1).
Cells were treated with probucol (10 µM) (Sigma), ERK1/2 inhibitor PD98058 (10 µM)
(Sigma), or mitochondrial division inhibitor mdivi-1 (10 µM) (Sigma) for 24 h prior to
biochemical and molecular assays.
2.2 Measurement of enzyme activities associated with respiratory chain complexes
Briefly, cybrid cells were washed with ice-cold PBS, and then harvested, centrifuged, and
suspended in 50 µL of isolation buffer containing 250 mM sucrose, 20 mM HEPES, and 1
mM EDTA. Cell suspensions (containing ~3–4 mg of protein/ml) were added to a cuvette
containing 0.95 mL of 1× assay buffer (10 mM Tris-HCl, and 120 mM KCl), and the
reaction volume was brought to 1.05 mL with the addition of 1× enzyme dilution buffer (10
mM Tris-HCl, pH 7.0). The reaction was then initiated by addition of 50 µL of
ferrocytochrome substrate solution (0.22 mM), and the change in absorbance of cytochrome
c at 550 nm was measured using a Shimadzu (Kyoto, Japan) UV1200 spectrophotometer.
Activity is expressed as micromoles of cytochrome oxidized per min−1 mg−1 protein using
an extinction coefficient of 27.84 mM−1 cm−1. Enzyme activities in complex I (NADH-
ubiquinone reductase), complex II (succinate dehydrogenase), complex III (ubiquinol-
cytochrome c reductase), complex IV (cytochrome c oxidase, CcO) and citrate synthase
activity were determined as described previously [23, 24].
2.3 Measurement of ATP levels
ATP levels were determined using an ATP Bioluminescence Assay Kit (Roche) following
the manufacturer’s instructions [2, 25]. Briefly, cells were harvested using the provided lysis
buffer, incubated on ice for 15 min, and centrifuged at 13,000 g for 10 min. ATP levels were
measured using a Luminescence plate reader (Molecular Devices) with an integration time
of 10 s.
2.4 Functional imaging
Cybrid cells were harvested from 75 cm2 flasks and replated at low density onto Lab-Tek
eight-well chamber slides. Mitochondrial ROS generation was determined using Mitosox
Red (Molecular Probes), a unique fluorogenic dye highly selective for detection of
superoxide production in live cell mitochondria. Cells were incubated with fresh growth
medium containing 2.5 µM Mitosox for 30 min. For mitochondrial membrane potential
determination, cells were co-stained with Mitotracker Green (MTGreen) (100 nM;
Molecular Probes) and TMRM (100 nM; Molecular Probes) for 30 min. Fluorescence from
MTGreen is independent of membrane potential, whereas TMRM is sensitive to membrane
potential. Mitochondria were labeled with Mitotracker Red (Molecular Probes, incubated in
100 nM Mitotracker Red for 30 min at 37 °C before fixation) to visualize morphology.
Images were captured under a microscope (Leica TCS SPE) using a 63X 1.4 NA
Apochrome objective (Carl Zeiss MicroImaging, Inc.). Excitation wavelengths were 543 nm
for Mitosox, TMRM or Mitotracker Red, and 488 nm for MTGreen, respectively.
Fluorescent signals were quantified using NIH Image J software. Post-acquisition processing
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was performed with MetaMorph (Molecular Devices) and NIH Image J software for
quantification and measurement of fluorescent signals of mitochondrial length and occupied
area. Mitochondrial size, shape, density, and fluorescent intensity were quantified by an
investigator blinded to experimental groups. More than 100 clearly identifiable mitochondria
from randomly selected 10–15 cells per experiment were measured in 3 independent
experiments.
2.5 Isolation of mitochondria and immunoblot analysis
Mitochondrial fraction and cytosol isolated from cybrid cells were suspended in buffer (150
mM KCl, 5 mM HEPES, 2 mM K2HPO4, 5 mM glutamate, 5 mM malate, 150 mM
potassium thiocyanate, pH 7.2), and subjected to the immunoblotting. The rabbit anti-DLP1
(1:3000, Thermo scientific), mouse anti-Mfn2 (1:2000, Sigma), mouse anti-Hsp60 (1:5000,
Enzo), rabbit anti-phospho-ERK1/2, mouse anti-ERK1/2 (1:2000, Cell signaling), and
mouse anti-β-actin (1:8000, Sigma) were used as primary antibodies. Binding sites of
primary antibody were visualized with horseradish peroxidase-conjugated anti-rabbit IgG
antibody (1:5000, life technology) or anti-mouse IgG antibody (1:5000, life technology)
followed by the addition of enhanced chemiluminescence (ECL) substrate (GE Healthcare).
We quantified relative optical density of immunoreactive bands using NIH Image J
software.
2.6 Mdivi-1 Treatment
Mdivi-1 was dissolved in DMSO (50 mM) and diluted with culture medium to the working
concentration. Cells were treated with mdiv-1 (10 µM) for 24–48 h, and mitochondrial
density, length, morphology, CcO activity, and ATP levels were determined as described
above.
2.7 Transient Transfection of mitochondrial fission construct (DLP1K38A)
Cells were transfected with plasmids containing GFP-tagged DLP1K38A (provided by Dr.
Yi-Ren Hong, Kaohsiung Medical University Hospital, Taiwan) or GFP-tagged empty
vector alone using Lipofectamine 2000 (Invitrogen) according to manufacturer’s
instructions. Forty-eight hours after transfection, cells were assessed for changes in
mitochondrial morphology or ATP levels as described above. Transfected cells were
visualized with green fluorescent protein (GFP) as reported [26].
2.8 Knockdown of DLP1 expression by siRNA-DLP1
The cybrid cells were transfected with SiRNA targeting human DLP1 (accession number
NM012062) or control siRNA (ON-TARGET Plus SMART Pool™, Dharmacon Research)
using Oligofectamine (Invitrogen) according to the manufacturer’s instructions. DLP1
silencing efficiency was evaluated by immunoblotting of DLP1 protein expression at 48 h
after siRNA transfection. In the parallel experiments, the mitochondrial morphology was
detected by immunostaining and Mitotracker Red staining.
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Data are presented as mean ± SEM. Statistical analysis was performed using Statview
software (SAS Institute, Version 5.0.1). Differences between means were assessed by
Student’s t-test or one-way analysis of variance (ANOVA) with Bonferroni/Dunn posthoc
test. P < 0.05 was considered significant.
3. Results
3.1 Mitochondrial Dysfunction in AD Cybrid Cells
We first characterized mitochondrial function by evaluating key enzymes associated with
respiratory chain, membrane potential, and bioenergy in newly created cybrid neuronal cells
containing AD or age-matched non-AD platelet mitochondria. Compared to non-AD
cybrids, AD neurons had a significant decrease in complex I, III, and IV activities (Fig. 1A–
C). No significant change in complex II activity was found in AD cybrid cells (Fig. S2A).
Similarly, ATP levels were reduced by 40–50% in AD cybrid cells (Fig. 1D). Citrate
synthase activity, used as a quantitative enzyme marker for the presence of intact
mitochondria, was comparable between AD and non-AD cybrids (Fig. S2B).
To more carefully evaluate mitochondrial function, we measured inner mitochondrial
membrane potential (ΔmΨm). Cells were treated with tetramethylrhodaminemethylester
(TMRM) to monitor mitochondrial membrane potential. TMRM staining was significantly
decreased in AD cybrids by 50–60% compared to non-AD cybrids (Fig.1E).
Given that mitochondria are a major source of ROS generation and that ROS accumulation
affects mitochondrial function, we tested whether mitochondrial ROS generation correlates
with mitochondrial dysfunction. Indeed, the intensity of Mitosox staining, an indicator for
mitochondrial ROS, was significantly increased in AD cybrids compared to non-AD control
cybrids (Fig. 1F).
3.2 Abnormal Mitochondrial Morphology and Mitochondrial Fission/Fusion Events in AD
Cybrid Neurons
Next, we evaluated changes in mitochondrial distribution and morphology. Mitochondrial
density in whole cell, cell body, and process was decreased in AD cybrid cells compared to
non-AD cells (Fig. 2A1–A3). Decreased mitochondrial density was more severe in processes
than in cell bodies (decreased by 40–50% in processes vs. 25–30% in cell bodies of AD
cybrids compared to non-AD (Fig. 2A2–A3). Morphologically, mitochondria in non-AD
cybrids were rod-like or elongated, and regularly distributed (Fig. 2B), whereas
mitochondria were fragmented, misshapen, bleb-like, and collapsed away from the
mitochondrial network in AD cybrid cells (Fig. 2B). Accordingly, mitochondrial length was
significantly shorter in AD cybrids than in non-AD controls (Fig. 2C1–C4), particularly in
neuronal process regions (Fig. 2C2).
Balance of mitochondrial fission and fusion proteins is critical for maintenance of normal
mitochondrial morphology [17, 27]. DLP1 is a key player in mitochondrial fission
regulation acting directly or indirectly with other fission/fusion proteins, and its
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translocation to mitochondria initiates the fission process [28]. Mitochondrial fraction and
cytosol from each cybrid cell line were isolated to assess fission and fusion protein levels
(Fig. 3). DLP1 levels were significantly increased in mitochondrial fraction of AD cybrids
(~1.5–1.6 fold) as compared to non-AD mitochondrial fraction. Accordingly, cytosolic
DLP1 was reduced in AD cybrids (Fig. 3A,C). Mfn2 that controls mitochondrial fusion was
significantly decreased in mitochondrial and increased in cytosolic fraction of AD cybrids
(Fig. 3B,D). Thus, both fission and fusion protein levels were altered in a direction favoring
mitochondrial fission in AD-derived mitochondria.
3.3 Effect of Antioxidant Treatment on Mitochondrial Function, Morphology, and Fission/
Fusion Proteins in AD Cybrid Cells
In view of increased mitochondrial ROS in AD cybrids and an important contributor of
oxidative stress to mitochondrial dysfunction and abnormal changes in mitochondrial
structure [2, 4, 5], we next determined if antioxidant treatment could rescue altered
mitochondrial function, morphology and fission/fusion dynamics. Cells were incubated with
the antioxidant probucol, which prevents lipid and protein oxidation [4, 5]. Probucol
treatment greatly attenuated mitochondrial ROS production/accumulation as shown by
reduced Mitosox intensity compared to vehicle-treated AD cybrid cells (Fig. 4A). Such
treatment significantly improved mitochondrial function and energy metabolism by
increased membrane potential (as measured by TMRM staining), complex I activity, and
ATP levels in AD cybrid cells (Fig. 4B–E). The protective effect of probucol on AD
mitochondria-induced dysfunction suggests the involvement of oxidative stress in
mitochondrial dysfunction.
We then evaluated the effect of probucol on mitochondrial density, length, and morphology.
Mitochondria density was significantly increased in probucol treated AD cybrid cells
compared to vehicle treatment (Fig. 4F). Similarly, the average mitochondrial length was
increased in AD cybrids (Fig. 4G). Abnormal mitochondrial morphology in AD
(fragmentation) cybrids was largely reversed compared to vehicle-treated AD cybrids (Fig.
4H), indicating the protective effect of antioxidant treatment on abnormal mitochondrial
morphology. As shown in Fig. 4I–J, probucol treatment significantly increased Mfn2 and
suppressed an increase in DLP1 expression in AD cybrids compared to the vehicle-treated
cells. These data demonstrate that antioxidant reverses impaired mitochondrial fission and
fusion dynamics in AD mitochondria.
3.4 Activation of ERK1/2 Signal Transduction is Responsible for Mitochondrial Fission/
Fusion Proteins Translocation and Defects in Mitochondrial Function
Oxidative stress induces activation of MAP kinase including extracellular receptor kinase
(ERK) and p38 [4, 29], which is linked to abnormal mitochondrial structure and function [4,
5, 30]. To examine the relatively unexplored role of ERK activation in AD-derived
mitochondria, we first analyzed ERK1/2 phosphorylation by immunoblotting. AD cybrid
cells exhibited significantly increased ERK1/2 phosphorylation (3–4 fold increase vs. non-
AD neurons). Addition of PD98059, a specific ERK inhibitor, largely abolished ERK1/2
phosphorylation (Fig. 5A). A total ERK1/2 was not significantly changed in AD cybrids
compared to non-AD cybrids. To determine the effect of oxidative stress on ERK1/2
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activation, cells were treated with probucol and then analyzed for phospho-ERK1/2.
Compared to vehicle treatment, probucol treatment significantly inhibited ERK1/2
phosphorylation in AD cybrid cells (Fig. 5B). The addition of PD98059 to the AD cybrid
cells blocked mitochondrial ROS generation (Fig. 5C). To assess if there is a direct link of
ERK1/2 activation to mitochondrial function, we examined the effect of ERK1/2 inhibitor
on mitochondrial membrane potential. Treatment with PD98059 resulted in a significantly
higher intensity of TMRM staining in AD cybrid cells than in vehicle-treated cells (Fig. 5D).
These results demonstrate that, in AD cybrids, ERK signaling transduction was perturbed
upon exposure to the oxidative stress.
Given that MAP Kinase signal pathway may be involved in regulating mitochondrial
function and mitochondrial fission/fusion protein expression [31], we hypothesized that
activation of the ERK pathway contributes to abnormal mitochondrial structure and function
observed in AD cybrids. To test this concept, we evaluated mitochondrial morphology and
mitochondrial fission/fusion protein expression levels in cybrid cells treated with PD98059.
As shown in Fig. 5E, mitochondrial density was increased in AD cybrid cells treated with
PD98059 compared to vehicle-treated cells. Similarly, PD98059 treatment increased
mitochondrial length in AD cybrids (Fig. 5F). Morphologically, there was a significant
reduction in mitochondrial fragmentation in AD cybrids (Fig. 5G). These data demonstrate
that inhibition of ERK activation effectively rescues alterations in mitochondrial
morphology in AD cybrids.
To explore the effect of ERK signal transduction on expression levels of mitochondrial
fission/fusion proteins in AD cybrids, we immunoblotted mitochondrial fractions for DLP1
and Mfn2 expression as described above. Consistent with the results shown in Fig. 3, DLP1
levels in AD mitochondrial fraction were significantly increased (~1.5–1.6 fold). In contrast,
PD98059 treatment reversed DLP1 expression levels compared to vehicle-treated cells (Fig.
5H), suggesting that inhibition of ERK activation rescues abnormal mitochondrial dynamics.
3.5 Treatment with Mitochondrial Division Inhibitor mdivi-1, DLP1K38A or siRNA-DLP1
Rescues Perturbations of Mitochondrial Function and Mitochondrial Fission/fusion Events
in AD Cybrids
Perturbed balance of mitochondrial fission and fusion is likely an important mechanism for
mitochondrial and neuronal dysfunction in AD brain [15, 17]. Results presented above raise
the question of whether such imbalance in mitochondrial fission/fusion in AD cybrids
affects mitochondrial function, and whether inhibition of mitochondrial division rescues
mitochondrial function defects. To address these questions, we investigated the effect of
mitochondrial division inhibitor, mdivi-1, a selective inhibitor of GTPase activity in DLP1
[32]. Treatment with mdivi-1 blocked mitochondrial fragmentation and improved
mitochondrial function induced by AD-derived mitochondrial defects. Mitochondrial length
and density were significantly increased in mdivi-1 treated AD cybrid neurons, as compared
to vehicle-treated cells (Fig. 6A–B). Accordingly, abnormal mitochondrial morphology was
significantly eradicated with the treatment with mdivi-1, as shown by reduction of
mitochondrial fragmentation in AD cybrids (Fig. 6C). Next, we evaluated mitochondrial
respiration chain activity and bioenergetic ability following treatment with mdivi-1. Deficits
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in complex IV activity and ATP levels were reversed by mdivi-1 treatment (Fig. 6D–E).
Consistent with these results, AD cybrid cells showed a significant increase in mitochondrial
membrane potential when exposed to mdivi-1 (Fig. 6F). Addition of mdivi-1 also
significantly suppressed ROS production in AD cybrids (Fig. 6G–H). Collectively, our data
indicate that mdivi-1 confers protective effects on mitochondrial structure and function
relevant to AD-derived mitochondrial toxicity.
To further validate the effect of DLP1 on abnormal mitochondrial dynamics that result in
mitochondrial morphological changes, we introduced a dominant negative protein defective
in GTP binding (DLPlK38A) to inhibit DLP1 GTPase activity or siRNA-targeted DLP1 to
knockdown DLP1 expression in AD cybrid cells. AD cybrid cells expressing DLP1K38A
rescued mitochondrial morphology as shown by the elongated mitochondria and reduced
mitochondrial fragmentation compared to empty vector transfected AD cybrid neurons (Fig.
7A–C). DLP1K38A-transfected cells increased CcO activity (Fig. 7D). Similar results were
obtained from siRNA-DLP1 treated cells (Fig. 7E–J). AD cells with reduced levels of DLP1
had an increase in the average of mitochondrial length and density as well as mitochondrial
membrane potential and ATP levels compared to the control siRNA treated cells. These
results indicate that disruption of DLP1 expression in AD- derived mitochondria may be
responsible for abnormal mitochondrial structure and function. We further tested whether
the blockade of DLP1 by pharmaceutical inhibitors or genetic knockdown of DLP1 affected
the ERK signaling in AD cybrids. There were no significant changes on phosphorylation
and expression levels of ERK1/2 under mdivi-1/ DLP1K38A/ siRNA-DLP1 experimental
conditions (Fig. S4), indicating that activation of ERK signaling may serve as an upstream
regulator of the ERK-DLP-1 pathway.
4. Discussion
Although abnormalities in mitochondrial structure and function in AD brain and AD mouse
models are well documented [2, 24, 33–35], the underlying mechanisms and the strategy to
rescue mitochondrial degeneration remain elusive. Particularly, the status of mitochondrial
fusion and fission pathway and its relationship between mitochondrial bioenergy and
mitochondrial morphology in human AD mitochondria have not been fully elucidated. Here,
we demonstrated the functional and metabolic differences in AD-derived mitochondria in
cybrid cells and the potential mechanisms by which AD mitochondria regulates
mitochondrial fission/fusion event through oxidative stress mediated activation of ERK-
DLP1 signal transduction.
First, we validated the consequence and impact of AD-derived mitochondrial defects on
mitochondrial structure and function using cybrid cell lines containing platelet mitochondria
from AD and age-matched subjects to repopulate mtDNA-free Rho0 neuroblastoma cells.
The resulting AD and non-AD cybrid cells have the same nuclear DNA background at the
time of experiments. Consistent with the previous report, these human neuronal cybrids
recapitulate many features observed in AD brain including impaired mitochondrial
respiratory function as shown by decreased enzyme activity associated with respiratory
chain [36, 37], decreased membrane potential and ATP levels, and increased mitochondrial
oxidative stress [38, 39]. The complex III activity was also declined in the platelet and
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lymphocyte prepared from AD patients [8]. Although there was one report that there is no
difference in the amount of complex III between AD and non-AD control brains [40], the
complex III activity could be significantly altered. For example, complex III activity was
significantly decreased in the brain of transgenic AD mouse model [24]. Thus, it requires
further investigation to analyze whether complex III enzyme activity is altered in AD
affected brain. Nevertheless, by using cybrid cells generated by fusing the Rho0 cells with
the AD-derived platelet mitochondria, we observe deficits in enzymatic activity associated
with respiratory chain including complex III, which is consistent with defect of complex III
activity founded in the platelet from AD patients [8].
Second, we demonstrated significant changes in mitochondrial morphology and fission/
fusion balance in AD cybrids. Defects in mitochondrial structure and function observed in
AD cybrid cells associate with altered expression and distribution of Mfn2 or DLP1. Third,
the structural and functional defects caused by AD mitochondria are protected by
antioxidant and inhibition of ERK1/2 activation. Importantly, pharmacological blockade of
mitochondrial division using mdivi-1, an inhibitor of DLP1 GTPase, and genetic restoration
with dominant negative DLP1K38A and knockdown of DLP1 expression rescue
mitochondrial morphology and function. Our current study provides new insights into the
human AD mitochondria-mediated structural and functional changes and identifies a
potential protective therapy against mitochondrial degeneration and improvement of
mitochondrial function relevant to the AD pathogenesis.
Morphologically, AD cybrids had fragmented, misshaped, and bleb-like mitochondria,
which are consistent with alterations in ultrastructure observed in AD neurons from human
brain and mouse models [30, 34, 35]. AD cybrid cells had lower mitochondrial density
compared to non-AD cybrids. To evaluate the possible effect on autophage/mitophagy, we
have performed immunostaining and immunoblotting of cybrid cells with autophagy marker
Light Chain (LC3). There are no significant changes in LC3 expression level or its
activation (Fig. S3), suggesting that there is no significant autophagy occurring in non-AD
or AD cybrid cells and that the mitochondrial density change may not associate with
mitophagy.
We explored the involvement of abnormal mitochondrial dynamics by investigating changes
in expression of mitochondrial fission and fusion proteins. AD cybrid cells showed an
increased DLP1 translocation to mitochondria, whereas Mfn2 expression was decreased in
AD cybrid mitochondria, suggesting that abnormal balance of mitochondrial fission and
fusion in AD cybrids. DLP1 exists primarily in the cytoplasm but partially associates into
foci on the outer surface of mitochondria that coalesce at sites of mitochondrial fission [28].
Increased DLP1 recruitment to mitochondria results in higher rates of DLP1-dependent
mitochondrial division and mitochondrial fragmentation [15]. Therefore, changes in DLP1
expression levels and distribution as well as changes in other fusion proteins, such as Mfn2,
likely contribute to enhanced mitochondrial fission, which may in turn be responsible for
fragmentation of mitochondria observed in AD cybrids.
Given that oxidative stress disrupts mitochondrial structure and function [2, 4, 5], we assess
whether antioxidant rescues oxidative stress-induced aberrant mitochondrial morphology
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and function. Probucol is an antioxidant preventing protein or lipid peroxidation and has
been clinically used during the past few decades for the treatment and prevention of
cardiovascular disease [41, 42]. Further, the addition of probucol attenuates Aβ- or AGE-
induced oxidative stress [4, 5, 43] and protects against ischemia-induced neuronal injury [4,
44]. Indeed, treatment with probucol significantly blunted mitochondrial ROS production,
and augmented mitochondrial membrane potential, respiratory chain complexes activities
and ATP production. Although the disruption of mitochondrial fission and fusion status in
Huntington’s disease is associated with increased ROS [45], to our knowledge this is the
first demonstration of the contribution of mitochondrial ROS to dysregulation of
mitochondrial fission and fusion induced by AD-derived mitochondria. Probucol treatment
rescued abnormal mitochondrial morphology by controlling mitochondrial fission and fusion
balance and associated protein expression levels, indicating that increased oxidative stress in
AD mitochondria is responsible for the perturbation of mitochondrial dynamics leading to
aberrant mitochondrial structure and function.
Activation of the MAP kinases ERK is associated with increased oxidative stress as well as
mitochondrial and neuronal stress [29, 46, 47]. We found that ERK1/2 phosphorylation was
significantly increased in AD cybrid cells. The antioxidant probucol blocked ERK1/2
activation along with attenuating mitochondrial perturbation, suggesting the impact of
oxidative stress on ERK signal transduction, leading to mitochondrial injury.
ERK activation correlates with increased mitochondrial fission and DLP1 translocation in α-
synuclein-mediated changes in mitochondrial dynamics [48]. Little is known about the ERK
signal-transduction pathways that may regulate mitochondrial fission/fusion dynamics in
AD-derived mitochondria. Given that blockade of ERK1/2 activation rescues mitochondrial
morphology by suppressing mitochondrial DLP1 levels in AD cybrids, we propose that
oxidative stress-mediated ERK activation augments DLP1 recruitment to mitochondria and
shifts mitochondrial dynamics toward excessive fission in AD, contributing to abnormal
mitochondrial morphology such as fragmentation of mitochondria. Abnormalities in
mitochondrial fission/fusion equilibrium precede functional defects in AD animal models.
Indeed, ERK inhibition accompanies functional recovery thereby supporting a pivotal
upstream role for ERK in regulation of mitochondrial function through influence on
mitochondrial dynamics. Taken together, we provide evidence that an axis of oxidative
stress, ERK and DLP1 signal transduction are critical to AD-related mitochondrial dynamic
imbalance and dysfunction (Fig. 8).
Inhibition of mitochondrial division using small molecule inhibitors (i.e., mdivi-1) in PD
and HD cell culture models or dominant negative forms of DLP1 in Aβ-impaired cell
culture models attenuates disease associated phenotypes [49–52]. Whether and how
attenuation of higher rates of mitochondrial division rescues defects associated with AD-
derived mitochondria has not yet been reported. In view of increased mitochondrial fraction
of DLP1 in AD cybrid and a key player of DLP1 in maintaining normal mitochondrial
dynamics, we examined the effect of mdivi-1, a selective inhibitor of GTPase activity in
DLP1 [32], on aberrant mitochondrial morphology and function. Treatment with mdivi-1
protects neurons from AD mitochondria-mediated injury. Furthermore, introduction of
DLP1K38A, or siRNA-DLP1 attenuated abnormal mitochondrial morphology and improved
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mitochondrial function, as shown by resultant inhibition of mitochondrial fragmentation,
and improved mitochondrial respiratory function and bioenergy. These data suggest that
blockade of DLP1 by pharmaceutical inhibitors or genetic knockdown of DLP1 can rescue
perturbation of mitochondrial defects. Taken together, our data support that DLP1 plays a
critical role in mitochondrial dynamic imbalance insulted by AD-derived mitochondria. The
protective effect of DLP1 on mitochondrial toxicity in human AD-derived mitochondria
suggests DLP1 as a potential and novel therapeutic target for AD.
In summary, our data offer new insights into structural and functional defects of human AD
mitochondria and the associated ERK-DLP1 signaling pathway. We provide substantial
evidence that the ERK pathway is involved in oxidative stress-induced DLP1 translocation
to mitochondria in AD cybrids. We hypothesize that increased oxidative stress in AD
mitochondria activates ERK signal transduction, disrupts mitochondrial fission and fusion
balance, and promotes translocation of DLP1 to mitochondria, leading to mitochondrial
fragmentation in AD. Most importantly, suppression of ERK signaling and inhibition of
mitochondrial fission pathways restore mitochondrial morphology and function induced by
AD mitochondrial defects (Fig.8). Thus, small molecule targeting to mitochondrial fission
(i.e., mdivi-1) may be a significant novel therapeutic strategy for AD treatment.
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1. Imbalance of mitochondrial dynamics contributes to AD mitochondrial
dysfunction
2. Activation of ERK/Dlp1 signaling disrupts proper mitochondrial dynamics
3. Antioxidant and suppressing ERK activation rescue mitochondrial morphology
and function
4. Inhibition of excessive mitochondrial fission protects against AD mitochondrial
defects
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Mitochondrial dysfunction in AD cybrid cells. A–D) Enzymatic activity of complex I, III,
and IV (CcO), and ATP levels were determined in cell lysates from indicated cell groups.
E–F) Mitochondrial membrane potential and reactive oxygen species (ROS) were measured
by TMRM (E) and Mitosox staining intensity (F), respectively. Image intensity was
quantified using NIH Image J software. Data are expressed as fold increase relative to non-
AD cybrid cells. N = 7 cell lines/group. * p<0.05 versus non-AD group.
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Abnormal mitochondrial morphology in AD cybrid cells. Cybrid cells were labeled with
Mitotracker Red for visualization of mitochondrial morphology. (A1–A3) Quantitative
measurement of mitochondrial density presented as the percentage of area occupied by
mitochondria in entire cells (A1), neuronal process (A2), or cell body (A3), using NIH
Image J software. B) Representative images of Mitotracker Red staining. Lower panels
present larger images corresponding to the indicated images above. Scale bar = 5 µm. (C1–
C3) Average mitochondrial length over the entire cell, neuronal processes, and cell body
was lower in AD cybrid cells compared to non-AD cells. (C4) Quantification of
mitochondrial sizes based on the grouped differently sized bins. N = 7 cell lines/group. *
p<0.05 versus non-AD group.
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DLP1 and Mfn2 expression levels in AD cybrid mitochondria. A–D) Densitometry of
immunoreactive bands for DLP1 (A, C) and Mfn2 (B, D) in mitochondrial fractions (A–B)
and cytosol (C–D) of indicated groups. Data were expressed as fold-increase of DLP1 or
Mfn2 relative to non-AD cells. DLP1 or Mfn2 levels were normalized to mitochondrial
marker Hsp60 or β-actin. Representative immunoblots are shown in lower panel. N = 7 cell
lines/group. *p<0.05 versus non-AD group.
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Effect of antioxidant treatment on mitochondrial function and morphology. A–B) Cells were
treated with probucol (10 µM) for 24 h and then stained with Mitosox or TMRM to
determine mitochondrial ROS levels and membrane potential. Quantification of staining
intensity for Mitosox (A) and TMRM (B) in the indicated groups of cells using NIH Image J
software. *p<0.05 versus all non-AD groups and probucol treated AD group. (C)
Representative images with TMRM staining (Scale bar = 10 µm). Mitotracker staining was
used to show mitochondria. D–E) Complex I activity (D) and ATP levels (E) were measured
in the indicated groups of cells with or without probucol treatment. Data are expressed as
fold increase relative to vehicle-treated non-AD cybrid cells. *p<0.05 versus all non-AD
groups and probucol treated AD group. F–H) Quantitative measurement of mitochondrial
density (F) and average mitochondrial length (G) in indicated cell groups using NIH Image
J. *p<0.05 versus all non-AD groups and probucol treated AD group. (H) Representative
images of Mitotracker Red staining. The lower panels present larger images corresponding
to indicated images above (Scale bar = 5µM). I–J) Quantification of immunoreactive bands
for Mfn2 (I) or DLP1 (J) relative to Hsp60 in indicated cell groups with probucol or vehicle
treatment using NIH Image J software. *, p<0.05 versus non-AD groups and probucol
treated AD group. Data are expressed as fold increase relative to vehicle-treated non-AD
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cybrid cells. Representative immunoblots are shown in the lower panel. N = 5–7 cell lines/
group.
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Inhibition of ERK activation rescued abnormal mitochondrial function and morphology. A–
B) Densitometry of immunoreactive bands for phospho-ERK1/2 (p-ERK1/2) using NIH
Image J, normalized to total-ERK1/2 (t-ERK1/2) in indicated cell groups treated with
PD98059 (10 µM for 2 h) (A), probucol (10 µM for 24 h) (B), or vehicle. *p<0.05 versus all
other groups. Representative immunoblots are shown in lower panel. C) PD98059 treatment
decreased Mitosox staining intensity in AD cybrid cells compared to vehicle treatment. (D)
TMRM staining intensity was significantly increased in AD cybrid cells treated with
PD98059. *p<0.05 versus all other groups. E–F) Effect of ERK inhibitor on mitochondrial
morphology. Mitochondrial density (E) and average length (F) were measured in indicated
cell groups treated with PD98059 or vehicle. *p<0.05 versus all other groups. (G)
Representative images are shown for Mitotracker Red staining. The lower panel is a larger
image corresponding to the indicated image above (Scale bar = 5 µm). H) Quantification of
immunoreactive bands for DLP1 and Mfn2 normalized to Hsp60 in mitochondrial fractions
of the indicated cell groups with PD98059 or vehicle treatment. Representative immunoblots
are shown in lower panel. Data are expressed as fold increase relative to vehicle-treated non-
AD cybrid cells. *p<0.05 versus all other groups. N = 5–7 cell lines/group.
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Inhibition of DLP1 by mdivi-1 rescues mitochondrial structure and function in AD cybrid
mitochondria. A–C) Effect of mdivi-1 on mitochondrial morphology. Mdivi-1 treatment (10
µM for 24 h) significantly increased mitochondrial length (A) and density (B)
Representative images for Mitotracker red staining reveal mitochondrial morphology (C).
*p<0.05 versus all other groups. The right panel is a larger image corresponding to the
indicated image on the left panel (Scale bar = 5 µm). D–H) Effect of mdivi-1 on
mitochondrial function. Treatment with mdiv-1 resulted in increased CcO activity (D), ATP
levels (E), and TMRM intensity in AD cybrid cells (F). Mdivi-1 also attenuated
mitochondrial ROS production as shown by reduced level of Mitosox staining intensity (G)
Representative images for Mitotracker and Mitosox staining are shown (H) (Scale bar = 10
µm). *p<0.05 versus all other groups. N = 5–7 cell lines/group.
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Effect of DLP1 blockade accomplished by introduction of DLP1K38A or siRNA-DLP1 to
AD cybrid cells. A–D) AD cybrid cells were transfected with GFP-DLP1K38A or empty
vector. After 24 h, cells were incubated with Mitotracker Red to analyze mitochondrial
morphology under confocal microscopy (Scale bar = 5 µm). DLP1K38A-transfected AD
cybrids had tubular mitochondria, whereas empty vector-transfected cells retained
fragmented mitochondrial morphology (A). Mitochondrial average length (B), density (C),
and CcO activity (D) were increased in DLP1K38A-transfected cells compared to vector-
transfected control cells. *p<0.05 versus vector treated group. E–J) Effect of siRNA-DLP1.
Immunoblotting for DLP1 in cells treated with siRNA-DLP1 (siRNA) or control siRNA
(con) (E). Representative immunoblots for DLP1 and β-actin. (F) Mitotracker staining and
immunostaining of DLP1 in siRNA-DLP1 or control siRNA treated cells (Scale bar = 5 µm).
Average mitochondrial length (G) and density (H).I–J), increased TMRM intensity (I), and
ATP levels (J) in siRNA-DLP1 cells relative to control siRNA cells. *p<0.05 versus vector
treated group. N = 5–7 cell lines/group.
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Working hypothesis: Increased mitochondrial ROS generation/accumulation is due to
defects in AD mitochondrial respiratory function, which leads to an activation of ERK
signal transduction. ERK activation directly or indirectly disrupts the balance of
mitochondrial dynamics (fusion and fission events) and results in altered DLP1 or Mfn2
expression levels and distribution, which eventually leads to aberrant mitochondrial
morphology and function. Inhibition of DLP1 activity/expression levels by mdivi-1 or
genetic blockade of DLP1 rescues the perturbation of mitochondrial morphology and
function relevant to AD mitochondrial degeneration.
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